Open Access News

News from the open access movement

Saturday, October 20, 2007

OA for drug data gleaned from journal literature

Free Access to Literature Data on Chagas' Disease Offered Online, a press release from Collaborative Drug Discovery, October 17, 2007.  Excerpt:

Collaborative Drug Discovery, Inc. (CDD, Inc.) has captured extensive literature data from six years of recent publications focused on the fight against Chagas' disease. Now for the first time these data are available to researchers free of charge, via the CDD Database.

Sources include the Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry, the Journal of American Chemical Society, Journal of Ethnopharmacology, Proceedings of the National Academy of Sciences (PNAS), International Journal of Antimicrobial Agents, Bioorganic & Medicinal Chemistry Letters, European Journal of Medicinal Chemistry, Molecular and Biochemical Parasitology, Journal of Inorganic Biochemistry, Acta Topical, and Experimental Parasitology.

The data sets captured include 574 compound structures and just over 350 different enzyme, cell, animal, and toxicity based protocols. The data are conveniently organized so scientists can easily mine for hits, sub-structural motifs or keywords and obtain the original literature reference for more detailed analysis....

This project is the first of a series literature data capture projects focused on drug discovery research into neglected infectious diseases. In addition to literature data, community members also provide open access to some of their experimental results either pre- or post-publication....

A significant subset of all the community data -- and a range of other data sets such as Chagas' data -- is available openly to the public at no cost. For this historical set of data either visit [here]....

Comment.  This is exciting.  I don't know whether CDD can harvest these data without publisher permission, on the ground that the data elements themselves are uncopyrightable facts, or whether publishers have granted permission, on the ground that access to the data advances research without undercutting subscriptions.  Either way it's good news.